Across TCGA pan-cancer cohorts, ANP32C Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated ANP32C data layer compared with 22 for mass-spec protein.
The strongest signal is observed in small cell lung cancer (SCLC), where higher ANP32C Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ANP32C expression acts as an unfavorable survival marker.
SCLC are the cancer types where ANP32C Mutation most reproducibly stratifies survival.